KR20160093025A - 멜랑코리성 특색을 갖는 우울 장애의 치료를 위한 카파-활성을 갖는 오피오이드 수용체 길항제 및 보티옥세틴의 용도 - Google Patents
멜랑코리성 특색을 갖는 우울 장애의 치료를 위한 카파-활성을 갖는 오피오이드 수용체 길항제 및 보티옥세틴의 용도 Download PDFInfo
- Publication number
- KR20160093025A KR20160093025A KR1020167016182A KR20167016182A KR20160093025A KR 20160093025 A KR20160093025 A KR 20160093025A KR 1020167016182 A KR1020167016182 A KR 1020167016182A KR 20167016182 A KR20167016182 A KR 20167016182A KR 20160093025 A KR20160093025 A KR 20160093025A
- Authority
- KR
- South Korea
- Prior art keywords
- kappa
- activity
- opioid antagonist
- treatment
- botyoxetine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 230000000694 effects Effects 0.000 title claims abstract description 147
- 239000003401 opiate antagonist Substances 0.000 title claims abstract description 129
- 238000011282 treatment Methods 0.000 title claims abstract description 90
- 208000020401 Depressive disease Diseases 0.000 title claims abstract description 53
- 229940123257 Opioid receptor antagonist Drugs 0.000 title description 4
- YQNWZWMKLDQSAC-UHFFFAOYSA-N vortioxetine Chemical compound CC1=CC(C)=CC=C1SC1=CC=CC=C1N1CCNCC1 YQNWZWMKLDQSAC-UHFFFAOYSA-N 0.000 title description 4
- 229960002263 vortioxetine Drugs 0.000 title description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 32
- WJBLNOPPDWQMCH-MBPVOVBZSA-N Nalmefene Chemical group N1([C@@H]2CC3=CC=C(C=4O[C@@H]5[C@](C3=4)([C@]2(CCC5=C)O)CC1)O)CC1CC1 WJBLNOPPDWQMCH-MBPVOVBZSA-N 0.000 claims description 66
- 229960005297 nalmefene Drugs 0.000 claims description 65
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 20
- DQCKKXVULJGBQN-XFWGSAIBSA-N naltrexone Chemical compound N1([C@@H]2CC3=CC=C(C=4O[C@@H]5[C@](C3=4)([C@]2(CCC5=O)O)CC1)O)CC1CC1 DQCKKXVULJGBQN-XFWGSAIBSA-N 0.000 claims description 15
- 229960003086 naltrexone Drugs 0.000 claims description 15
- 239000002552 dosage form Substances 0.000 claims description 13
- UZHSEJADLWPNLE-GRGSLBFTSA-N naloxone Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(O)C2=C5[C@@]13CCN4CC=C UZHSEJADLWPNLE-GRGSLBFTSA-N 0.000 claims description 12
- 229960004127 naloxone Drugs 0.000 claims description 12
- APSUXPSYBJVPPS-YAUKWVCOSA-N Norbinaltorphimine Chemical compound N1([C@@H]2CC3=CC=C(C=4O[C@@H]5[C@](C3=4)([C@]2(CC=2C=3C[C@]4(O)[C@]67CCN(CC8CC8)[C@@H]4CC=4C7=C(C(=CC=4)O)O[C@H]6C=3NC=25)O)CC1)O)CC1CC1 APSUXPSYBJVPPS-YAUKWVCOSA-N 0.000 claims description 11
- RMRJXGBAOAMLHD-IHFGGWKQSA-N buprenorphine Chemical compound C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]11CC[C@]3([C@H](C1)[C@](C)(O)C(C)(C)C)OC)CN2CC1CC1 RMRJXGBAOAMLHD-IHFGGWKQSA-N 0.000 claims description 10
- 229960001736 buprenorphine Drugs 0.000 claims description 10
- 230000001419 dependent effect Effects 0.000 claims description 9
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 9
- OZYUPQUCAUTOBP-QXAKKESOSA-N Levallorphan Chemical compound C([C@H]12)CCC[C@@]11CCN(CC=C)[C@@H]2CC2=CC=C(O)C=C21 OZYUPQUCAUTOBP-QXAKKESOSA-N 0.000 claims description 5
- 229960000263 levallorphan Drugs 0.000 claims description 5
- 239000003887 narcotic antagonist Substances 0.000 abstract description 21
- 230000035882 stress Effects 0.000 description 49
- 241001465754 Metazoa Species 0.000 description 48
- 229930006000 Sucrose Natural products 0.000 description 34
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 34
- 239000005720 sucrose Substances 0.000 description 34
- 238000000034 method Methods 0.000 description 32
- 239000003814 drug Substances 0.000 description 30
- 150000001875 compounds Chemical class 0.000 description 29
- 102000048260 kappa Opioid Receptors Human genes 0.000 description 24
- 108020001588 κ-opioid receptors Proteins 0.000 description 24
- 229940079593 drug Drugs 0.000 description 22
- 239000003981 vehicle Substances 0.000 description 20
- 238000012360 testing method Methods 0.000 description 19
- 239000000203 mixture Substances 0.000 description 15
- 230000001684 chronic effect Effects 0.000 description 14
- 230000001568 sexual effect Effects 0.000 description 14
- 239000000243 solution Substances 0.000 description 14
- 208000024891 symptom Diseases 0.000 description 14
- 208000007848 Alcoholism Diseases 0.000 description 13
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 13
- BCGWQEUPMDMJNV-UHFFFAOYSA-N imipramine Chemical compound C1CC2=CC=CC=C2N(CCCN(C)C)C2=CC=CC=C21 BCGWQEUPMDMJNV-UHFFFAOYSA-N 0.000 description 13
- 201000007930 alcohol dependence Diseases 0.000 description 12
- 229960004801 imipramine Drugs 0.000 description 12
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 12
- 206010002091 Anaesthesia Diseases 0.000 description 10
- 230000037005 anaesthesia Effects 0.000 description 10
- 239000003826 tablet Substances 0.000 description 10
- 238000002560 therapeutic procedure Methods 0.000 description 9
- -1 2,4-Dimethyl-phenylsulfanyl Chemical group 0.000 description 8
- 208000035475 disorder Diseases 0.000 description 8
- 239000007788 liquid Substances 0.000 description 8
- 230000036651 mood Effects 0.000 description 8
- 230000009467 reduction Effects 0.000 description 8
- 239000007787 solid Substances 0.000 description 8
- 230000001225 therapeutic effect Effects 0.000 description 8
- UIQMVEYFGZJHCZ-SSTWWWIQSA-N Nalorphine Chemical compound C([C@@H](N(CC1)CC=C)[C@@H]2C=C[C@@H]3O)C4=CC=C(O)C5=C4[C@@]21[C@H]3O5 UIQMVEYFGZJHCZ-SSTWWWIQSA-N 0.000 description 7
- 239000003085 diluting agent Substances 0.000 description 7
- 238000009472 formulation Methods 0.000 description 7
- 239000012458 free base Substances 0.000 description 7
- 208000024714 major depressive disease Diseases 0.000 description 7
- 230000008450 motivation Effects 0.000 description 7
- 229960000938 nalorphine Drugs 0.000 description 7
- 239000004480 active ingredient Substances 0.000 description 6
- 239000005557 antagonist Substances 0.000 description 6
- 210000004556 brain Anatomy 0.000 description 6
- 230000000994 depressogenic effect Effects 0.000 description 6
- 239000003937 drug carrier Substances 0.000 description 6
- 235000013305 food Nutrition 0.000 description 6
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
- 239000004031 partial agonist Substances 0.000 description 6
- 208000020016 psychiatric disease Diseases 0.000 description 6
- 150000003839 salts Chemical class 0.000 description 6
- 241000283984 Rodentia Species 0.000 description 5
- 239000007864 aqueous solution Substances 0.000 description 5
- 239000002775 capsule Substances 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 238000007917 intracranial administration Methods 0.000 description 5
- 238000007912 intraperitoneal administration Methods 0.000 description 5
- 102000051367 mu Opioid Receptors Human genes 0.000 description 5
- 238000007920 subcutaneous administration Methods 0.000 description 5
- 108020001612 μ-opioid receptors Proteins 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 239000002671 adjuvant Substances 0.000 description 4
- 238000010171 animal model Methods 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- 239000000969 carrier Substances 0.000 description 4
- 230000003001 depressive effect Effects 0.000 description 4
- 235000014113 dietary fatty acids Nutrition 0.000 description 4
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 4
- 239000000839 emulsion Substances 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 239000000194 fatty acid Substances 0.000 description 4
- 229930195729 fatty acid Natural products 0.000 description 4
- 239000000902 placebo Substances 0.000 description 4
- 229940068196 placebo Drugs 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 230000000750 progressive effect Effects 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 230000000638 stimulation Effects 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 239000006188 syrup Substances 0.000 description 4
- 235000020357 syrup Nutrition 0.000 description 4
- 206010054089 Depressive symptom Diseases 0.000 description 3
- 108010010803 Gelatin Proteins 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- 208000019022 Mood disease Diseases 0.000 description 3
- 235000019483 Peanut oil Nutrition 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 101100244562 Pseudomonas aeruginosa (strain ATCC 15692 / DSM 22644 / CIP 104116 / JCM 14847 / LMG 12228 / 1C / PRS 101 / PAO1) oprD gene Proteins 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 230000037326 chronic stress Effects 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 108700023159 delta Opioid Receptors Proteins 0.000 description 3
- 102000048124 delta Opioid Receptors Human genes 0.000 description 3
- 239000006185 dispersion Substances 0.000 description 3
- 239000003623 enhancer Substances 0.000 description 3
- 239000008273 gelatin Substances 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 235000011852 gelatine desserts Nutrition 0.000 description 3
- 230000000977 initiatory effect Effects 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- 235000019359 magnesium stearate Nutrition 0.000 description 3
- 230000003340 mental effect Effects 0.000 description 3
- 239000000312 peanut oil Substances 0.000 description 3
- 230000002085 persistent effect Effects 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 230000009257 reactivity Effects 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 230000002787 reinforcement Effects 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 239000000454 talc Substances 0.000 description 3
- 235000012222 talc Nutrition 0.000 description 3
- 229910052623 talc Inorganic materials 0.000 description 3
- 238000012549 training Methods 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- IZHVBANLECCAGF-UHFFFAOYSA-N 2-hydroxy-3-(octadecanoyloxy)propyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)COC(=O)CCCCCCCCCCCCCCCCC IZHVBANLECCAGF-UHFFFAOYSA-N 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 2
- 229920002261 Corn starch Polymers 0.000 description 2
- 229920000858 Cyclodextrin Polymers 0.000 description 2
- 108010049140 Endorphins Proteins 0.000 description 2
- 102000009025 Endorphins Human genes 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical class Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 2
- 240000007472 Leucaena leucocephala Species 0.000 description 2
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 2
- 208000036626 Mental retardation Diseases 0.000 description 2
- 102000003840 Opioid Receptors Human genes 0.000 description 2
- 108090000137 Opioid Receptors Proteins 0.000 description 2
- 208000005374 Poisoning Diseases 0.000 description 2
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 2
- 102100024622 Proenkephalin-B Human genes 0.000 description 2
- 241000700157 Rattus norvegicus Species 0.000 description 2
- 235000021355 Stearic acid Nutrition 0.000 description 2
- 206010068932 Terminal insomnia Diseases 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- 235000010419 agar Nutrition 0.000 description 2
- 238000013019 agitation Methods 0.000 description 2
- 239000000556 agonist Substances 0.000 description 2
- 150000005215 alkyl ethers Chemical class 0.000 description 2
- 208000022531 anorexia Diseases 0.000 description 2
- 230000008503 anti depressant like effect Effects 0.000 description 2
- 239000000935 antidepressant agent Substances 0.000 description 2
- 229940005513 antidepressants Drugs 0.000 description 2
- 230000003542 behavioural effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000004927 clay Substances 0.000 description 2
- 208000010877 cognitive disease Diseases 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 239000008120 corn starch Substances 0.000 description 2
- 206010061428 decreased appetite Diseases 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 229960003638 dopamine Drugs 0.000 description 2
- 230000035622 drinking Effects 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 239000007903 gelatin capsule Substances 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 238000005286 illumination Methods 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 239000002618 kappa opiate receptor antagonist Substances 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 239000007937 lozenge Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000003607 modifier Substances 0.000 description 2
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 2
- 239000004006 olive oil Substances 0.000 description 2
- 235000008390 olive oil Nutrition 0.000 description 2
- 239000006186 oral dosage form Substances 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 239000001814 pectin Substances 0.000 description 2
- 235000010987 pectin Nutrition 0.000 description 2
- 229920001277 pectin Polymers 0.000 description 2
- 150000003904 phospholipids Chemical class 0.000 description 2
- 231100000572 poisoning Toxicity 0.000 description 2
- 230000000607 poisoning effect Effects 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 239000000018 receptor agonist Substances 0.000 description 2
- 229940044601 receptor agonist Drugs 0.000 description 2
- 229940044551 receptor antagonist Drugs 0.000 description 2
- 239000002464 receptor antagonist Substances 0.000 description 2
- 239000012744 reinforcing agent Substances 0.000 description 2
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 2
- 229940076279 serotonin Drugs 0.000 description 2
- 239000008117 stearic acid Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 235000021147 sweet food Nutrition 0.000 description 2
- 230000004580 weight loss Effects 0.000 description 2
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 1
- GYWMRGWFQPSQLK-OPHZJPRHSA-N (4r,4as,7as,12bs)-3-(cyclopropylmethyl)-7-methylidene-2,4,5,6,7a,13-hexahydro-1h-4,12-methanobenzofuro[3,2-e]isoquinoline-4a,9-diol;hydron;chloride Chemical compound Cl.N1([C@@H]2CC3=CC=C(C=4O[C@@H]5[C@](C3=4)([C@]2(CCC5=C)O)CC1)O)CC1CC1 GYWMRGWFQPSQLK-OPHZJPRHSA-N 0.000 description 1
- JWDYCNIAQWPBHD-UHFFFAOYSA-N 1-(2-methylphenyl)glycerol Chemical compound CC1=CC=CC=C1OCC(O)CO JWDYCNIAQWPBHD-UHFFFAOYSA-N 0.000 description 1
- 125000004208 3-hydroxyphenyl group Chemical group [H]OC1=C([H])C([H])=C([H])C(*)=C1[H] 0.000 description 1
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical class N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 1
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 206010002869 Anxiety symptoms Diseases 0.000 description 1
- 108030001720 Bontoxilysin Proteins 0.000 description 1
- 208000028698 Cognitive impairment Diseases 0.000 description 1
- 206010010144 Completed suicide Diseases 0.000 description 1
- 206010012335 Dependence Diseases 0.000 description 1
- 108010065372 Dynorphins Proteins 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 108090000189 Neuropeptides Proteins 0.000 description 1
- 102000003797 Neuropeptides Human genes 0.000 description 1
- HLMSIZPQBSYUNL-IPOQPSJVSA-N Noroxymorphone Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(O)C2=C5[C@@]13CCN4 HLMSIZPQBSYUNL-IPOQPSJVSA-N 0.000 description 1
- 229940127450 Opioid Agonists Drugs 0.000 description 1
- 208000026251 Opioid-Related disease Diseases 0.000 description 1
- 208000004756 Respiratory Insufficiency Diseases 0.000 description 1
- 206010038678 Respiratory depression Diseases 0.000 description 1
- 102000019208 Serotonin Plasma Membrane Transport Proteins Human genes 0.000 description 1
- 108010012996 Serotonin Plasma Membrane Transport Proteins Proteins 0.000 description 1
- 244000000231 Sesamum indicum Species 0.000 description 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 238000007239 Wittig reaction Methods 0.000 description 1
- 230000004308 accommodation Effects 0.000 description 1
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 1
- 229960004373 acetylcholine Drugs 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 230000000949 anxiolytic effect Effects 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 230000037007 arousal Effects 0.000 description 1
- 229940125717 barbiturate Drugs 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 229940053031 botulinum toxin Drugs 0.000 description 1
- 229940081709 brintellix Drugs 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 210000003710 cerebral cortex Anatomy 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000011260 co-administration Methods 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 230000001149 cognitive effect Effects 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 239000012050 conventional carrier Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 235000019788 craving Nutrition 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 239000007933 dermal patch Substances 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- NSNHWTBQMQIDCF-UHFFFAOYSA-N dihydrate;hydrochloride Chemical class O.O.Cl NSNHWTBQMQIDCF-UHFFFAOYSA-N 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 230000007783 downstream signaling Effects 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 206010013663 drug dependence Diseases 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 108010025394 dynorphin receptor Proteins 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 239000006274 endogenous ligand Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000005713 exacerbation Effects 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229940074045 glyceryl distearate Drugs 0.000 description 1
- 229940075507 glyceryl monostearate Drugs 0.000 description 1
- 239000000380 hallucinogen Substances 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 229940102223 injectable solution Drugs 0.000 description 1
- 229940125425 inverse agonist Drugs 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 238000010150 least significant difference test Methods 0.000 description 1
- 239000008297 liquid dosage form Substances 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 238000000491 multivariate analysis Methods 0.000 description 1
- 229960000677 nalmefene hydrochloride Drugs 0.000 description 1
- 229950010675 nalmefene hydrochloride dihydrate Drugs 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- HYIMSNHJOBLJNT-UHFFFAOYSA-N nifedipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1[N+]([O-])=O HYIMSNHJOBLJNT-UHFFFAOYSA-N 0.000 description 1
- 229960001597 nifedipine Drugs 0.000 description 1
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 1
- 229960002748 norepinephrine Drugs 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 229940127240 opiate Drugs 0.000 description 1
- 239000003402 opiate agonist Substances 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 238000011422 pharmacological therapy Methods 0.000 description 1
- 238000011458 pharmacological treatment Methods 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 239000012758 reinforcing additive Substances 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000011808 rodent model Methods 0.000 description 1
- 239000005060 rubber Substances 0.000 description 1
- 239000004001 serotonin 1D antagonist Substances 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 230000003997 social interaction Effects 0.000 description 1
- 239000007909 solid dosage form Substances 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 208000011117 substance-related disease Diseases 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 230000009182 swimming Effects 0.000 description 1
- 230000005062 synaptic transmission Effects 0.000 description 1
- 230000004797 therapeutic response Effects 0.000 description 1
- 230000035922 thirst Effects 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- ODLHGICHYURWBS-LKONHMLTSA-N trappsol cyclo Chemical compound CC(O)COC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)COCC(O)C)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1COCC(C)O ODLHGICHYURWBS-LKONHMLTSA-N 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Emergency Medicine (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Addiction (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA201300710 | 2013-12-20 | ||
| DKPA201300710 | 2013-12-20 | ||
| DKPA201400590 | 2014-10-16 | ||
| DKPA201400590 | 2014-10-16 | ||
| PCT/EP2014/078515 WO2015091833A1 (en) | 2013-12-20 | 2014-12-18 | Use of an opioid receptor antagonist with kappa-activity and vortioxetine for treatment of depressive disorder with melancholic features |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20160093025A true KR20160093025A (ko) | 2016-08-05 |
Family
ID=52146489
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020167016182A Withdrawn KR20160093025A (ko) | 2013-12-20 | 2014-12-18 | 멜랑코리성 특색을 갖는 우울 장애의 치료를 위한 카파-활성을 갖는 오피오이드 수용체 길항제 및 보티옥세틴의 용도 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US10376506B2 (enExample) |
| EP (1) | EP3082815B1 (enExample) |
| JP (1) | JP6448645B2 (enExample) |
| KR (1) | KR20160093025A (enExample) |
| CN (1) | CN105828821B (enExample) |
| AU (1) | AU2014368548B2 (enExample) |
| CA (1) | CA2933733A1 (enExample) |
| CL (1) | CL2016001570A1 (enExample) |
| ES (1) | ES2694352T3 (enExample) |
| IL (1) | IL246253A0 (enExample) |
| MX (1) | MX368870B (enExample) |
| RU (1) | RU2679661C1 (enExample) |
| SG (1) | SG11201604944PA (enExample) |
| WO (1) | WO2015091833A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112018003930A2 (pt) * | 2016-07-01 | 2018-09-25 | H Lundbeck As | regimes de dosagem de vortioxetina para início rápido de efeito antidepressivo |
| EP3870292A4 (en) | 2018-10-26 | 2022-11-09 | The Research Foundation for The State University of New York | COMBINATION OF SEROTONIN-SPECIFIC RESUPPUT INHIBITOR AND SEROTONIN 1A RECEPTOR PARTIAL AGONIST TO REDUCE L-DOPA-INDUCED DYSKINESIA |
| JP7549576B2 (ja) | 2018-11-06 | 2024-09-11 | パーデュー、ファーマ、リミテッド、パートナーシップ | オピオイドアンタゴニストを送達するための組成物及び方法 |
| US11266627B1 (en) | 2021-05-04 | 2022-03-08 | Janssen Pharmaceuticals, Inc. | Compositions and methods for the treatment of depression |
| US12161622B2 (en) | 2021-05-04 | 2024-12-10 | Janssen Pharmaceuticals, Inc. | Compositions and methods for the treatment of depression |
| WO2023170550A1 (en) | 2022-03-07 | 2023-09-14 | Janssen Pharmaceuticals, Inc. | Polymorph forms of aticaprant for use in treating major depressive disorder |
| TW202400135A (zh) | 2022-03-07 | 2024-01-01 | 美商健生醫藥公司 | 包含阿替卡普蘭之組成物 |
| TW202547487A (zh) * | 2024-03-18 | 2025-12-16 | 學校法人東京理科大學 | 失樂症的治療或預防用醫藥組成物 |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5013740A (en) | 1990-03-22 | 1991-05-07 | Hillel Glover | Method for treating emotional numbness and coma |
| US5028612A (en) | 1990-03-22 | 1991-07-02 | Hillel Glover | Method for treating emotional numbness |
| US5512593A (en) * | 1993-03-02 | 1996-04-30 | John S. Nagle | Composition and method of treating depression using natoxone or naltrexone in combination with a serotonin reuptake inhibitor |
| US6528518B2 (en) * | 2000-12-21 | 2003-03-04 | The Mclean Hospital Corporation | Treatment of depression with kappa receptor antagonists |
| US20030087896A1 (en) | 2001-08-09 | 2003-05-08 | Hillel Glover | Treatment of refractory depression with an opiate antagonist and an antidepressant |
| PL368612A1 (en) * | 2001-08-14 | 2005-04-04 | Biotie Therapies Corporation | Method of treating alcoholism or alcohol abuse |
| UA81749C2 (uk) | 2001-10-04 | 2008-02-11 | Х. Луннбек А/С | Фенілпіперазинові похідні як інгібітори зворотного захоплення серотоніну |
| DK1485051T3 (da) * | 2002-03-20 | 2008-09-08 | Euro Celtique Sa | Fremgangsmåde til indgivelse af buprenorphin til behandling af depression |
| US20080045610A1 (en) * | 2004-09-23 | 2008-02-21 | Alexander Michalow | Methods for regulating neurotransmitter systems by inducing counteradaptations |
| US20070179168A1 (en) * | 2005-11-28 | 2007-08-02 | Orexigen Therapeutics, Inc. | Methods of treating anxiety disorders |
| CN101432011A (zh) * | 2006-02-27 | 2009-05-13 | 亚历山大·米哈洛 | 通过诱导逆适应调节神经递质系统的方法 |
| WO2008066916A1 (en) | 2006-11-30 | 2008-06-05 | The Mclean Hospital Corporation | Methods for the treatment of mood disorders |
| DE502007002185D1 (de) * | 2006-04-04 | 2010-01-14 | Emodys Gmbh | Verwendung von zusammensetzungen enthaltend kappa-opioidrezeptor-antagonisten zur behandlung von dissoziativen störungen |
| US20070259939A1 (en) * | 2006-05-04 | 2007-11-08 | Accelerated Technologies | Using naltrexone as a multi-purpose health supplement to improve the human condition and preventing multiple diseases and infirmities by stimulating immune system vitality and robustness |
| KR101627901B1 (ko) | 2006-06-16 | 2016-06-13 | 하. 룬트벡 아크티에 셀스카브 | 인지기능 장애의 치료를 위한, 세로토닌 재흡수, 5-ht3 및 5-ht1a 활성이 조합된 화합물로서의 1-[2-(2,4-디메틸페닐술파닐)-페닐]피페라진 |
| TW200848411A (en) | 2007-03-20 | 2008-12-16 | Lundbeck & Co As H | Novel therapeutic uses of 1-[2-(2, 4-dimethylphenylsulfanyl)phenyl]-piperazine |
| TW200932233A (en) * | 2007-11-13 | 2009-08-01 | Lundbeck & Co As H | Therapeutic uses of compounds having combined SERT, 5-HT3 and 5-HT1a activity |
| TW200932225A (en) * | 2007-12-14 | 2009-08-01 | Lundbeck & Co As H | 4-[2,3-difluoro-6-(2-fluoro-4-methyl-phenylsulfanyl)-phenyl]-piperidine |
| MY158251A (en) | 2009-05-25 | 2016-09-30 | H Lundbeck As | Method for the preparation of nalmefene hydrochloride |
| WO2011020030A2 (en) * | 2009-08-13 | 2011-02-17 | The General Hospital Corporation | Methods and compositions to prevent addiction |
| WO2011136376A1 (ja) | 2010-04-30 | 2011-11-03 | 武田薬品工業株式会社 | 腸溶性錠剤 |
| RS55777B1 (sr) | 2010-11-05 | 2017-07-31 | H Lundbeck As | Postupak za proizvodnju naltreksona |
| JP6406713B2 (ja) * | 2013-01-30 | 2018-10-17 | ファーモレックス セラピューティクス， インコーポレイテッド | 低用量薬剤によるうつ病および他の疾患の処置 |
| WO2014170351A1 (en) * | 2013-04-17 | 2014-10-23 | H. Lundbeck A/S | Nalmefene for treatment of patients with mood disorder |
| CA2909506C (en) | 2013-04-17 | 2021-04-20 | H. Lundbeck A/S | Nalmefene for treatment of patients with anxiety disorder |
-
2014
- 2014-12-18 MX MX2016007947A patent/MX368870B/es active IP Right Grant
- 2014-12-18 WO PCT/EP2014/078515 patent/WO2015091833A1/en not_active Ceased
- 2014-12-18 JP JP2016540981A patent/JP6448645B2/ja active Active
- 2014-12-18 ES ES14818973.1T patent/ES2694352T3/es active Active
- 2014-12-18 RU RU2016123972A patent/RU2679661C1/ru not_active IP Right Cessation
- 2014-12-18 SG SG11201604944PA patent/SG11201604944PA/en unknown
- 2014-12-18 CA CA2933733A patent/CA2933733A1/en not_active Abandoned
- 2014-12-18 AU AU2014368548A patent/AU2014368548B2/en not_active Ceased
- 2014-12-18 US US15/105,701 patent/US10376506B2/en active Active
- 2014-12-18 EP EP14818973.1A patent/EP3082815B1/en active Active
- 2014-12-18 CN CN201480069586.5A patent/CN105828821B/zh active Active
- 2014-12-18 KR KR1020167016182A patent/KR20160093025A/ko not_active Withdrawn
-
2016
- 2016-06-15 IL IL246253A patent/IL246253A0/en unknown
- 2016-06-17 CL CL2016001570A patent/CL2016001570A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ES2694352T3 (es) | 2018-12-20 |
| CA2933733A1 (en) | 2015-06-25 |
| JP6448645B2 (ja) | 2019-01-09 |
| AU2014368548A1 (en) | 2016-06-30 |
| SG11201604944PA (en) | 2016-07-28 |
| CL2016001570A1 (es) | 2016-12-09 |
| MX2016007947A (es) | 2016-09-09 |
| EP3082815A1 (en) | 2016-10-26 |
| AU2014368548B2 (en) | 2019-09-19 |
| JP2016540030A (ja) | 2016-12-22 |
| US20160310488A1 (en) | 2016-10-27 |
| EP3082815B1 (en) | 2018-10-03 |
| CN105828821A (zh) | 2016-08-03 |
| US10376506B2 (en) | 2019-08-13 |
| MX368870B (es) | 2019-10-21 |
| RU2016123972A (ru) | 2018-01-25 |
| WO2015091833A1 (en) | 2015-06-25 |
| IL246253A0 (en) | 2016-07-31 |
| CN105828821B (zh) | 2019-04-09 |
| RU2679661C1 (ru) | 2019-02-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3082815B1 (en) | Use of an opioid receptor antagonist with kappa-activity and vortioxetine for treatment of depressive disorder with melancholic features | |
| Rorarius et al. | Gabapentin for the prevention of postoperative pain after vaginal hysterectomy | |
| JP2024091801A (ja) | 物質乱用の治療方法 | |
| WO2007005716A2 (en) | Methods of treatment and compositions for use thereof | |
| Khatri et al. | Xylazine suppresses fentanyl consumption during self-administration and induces a unique sex-specific withdrawal syndrome that is not altered by naloxone in rats. | |
| Endoh et al. | Characterization of the antinociceptive effects of TRK-820 in the rat | |
| Nguyen et al. | Evaluation of therapies for peripheral and neuraxial opioid-induced pruritus based on molecular and cellular discoveries | |
| Fischer et al. | Effects of N-methyl-D-aspartate receptor antagonists on acute morphine-induced and l-methadone-induced antinociception in mice | |
| Fiorino et al. | Muscarinic pain pharmacology: realizing the promise of novel analgesics by overcoming old challenges | |
| Varshneya et al. | Structurally diverse fentanyl analogs yield differential locomotor activities in mice | |
| Kong et al. | Low-dose butorphanol alleviates remifetanil-induced hyperalgesia in patients undergoing laparoscopic cholecystectomy | |
| H Rezvani et al. | Novel medication targets for the treatment of alcoholism: preclinical studies | |
| KR102266696B1 (ko) | 주의력 및 인지 장애, 및 신경 퇴행성 장애와 관련된 치매 치료용 신규 치료제 | |
| Ko et al. | Local administration of mu or kappa opioid agonists attenuates capsaicin-induced thermal hyperalgesia via peripheral opioid receptors in rats | |
| RU2322977C1 (ru) | Синтетическое анальгетическое средство и способ лечения на основе этого средства | |
| Aubel et al. | Evidence for adenosine-and serotonin-mediated antihyperalgesic effects of cizolirtine in rats suffering from diabetic neuropathy | |
| HK1229240A1 (en) | Use of an opioid receptor antagonist with kappa-activity and vortioxetine for treatment of depressive disorder with melancholic features | |
| HK1229240B (en) | Use of an opioid receptor antagonist with kappa-activity and vortioxetine for treatment of depressive disorder with melancholic features | |
| Loots et al. | Agents for sedation in ophthalmic surgery: a review of the pharmacodynamics and clinical applications | |
| Minto et al. | New opioid analgesics: an update | |
| EP1942891B1 (en) | Novel combination of drugs as antidepressant | |
| Trick et al. | Pharmacological treatment of alcohol use disorder | |
| JP6416213B2 (ja) | 気分障害患者の治療のためのナルメフェン | |
| Siddu | Evaluation of Buprenorphine Added to Lignocaine for Post Operative Analgesia After Lower Third Molar Surgery | |
| US20110046173A1 (en) | Combination analgesic opioid pain therapy |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
Patent event date: 20160617 Patent event code: PA01051R01D Comment text: International Patent Application |
|
| PG1501 | Laying open of application | ||
| PC1203 | Withdrawal of no request for examination | ||
| WITN | Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid |